


**AMENDMENTS TO THE CLAIMS**

**LISTING OF CLAIMS:**

1. (currently amended): A solid oral dosage form pharmaceutical for the treatment of



dysuria, which comprises, as an active ingredient, an indoline compound having an  $\alpha_1$ -adrenoceptor blocking activity and represented by the formula:

a prodrug thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, wherein 85% dissolution time is not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using water as a test medium and a paddle speed of 50rpm.

2. (original): The pharmaceutical according to claim 1, wherein 85% dissolution time is not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using the first fluid regulated in a disintegration test of Japanese pharmacopoeia as a test medium and a paddle speed of 50rpm.

3. (currently amended): The pharmaceutical according to claim 1-~~or~~2, wherein 85% dissolution time is not more than 30 minutes.

PRELIMINARY AMENDMENT  
National Stage Application of  
PCT/JP2003/015837

4. (original): The pharmaceutical according to claim 3, wherein 85% dissolution time is not more than 15 minutes.

5. (currently amended): The pharmaceutical according to ~~any one of claims 1 to 4~~ claim 1, which comprises D-mannitol as a filler.

6. (original): The pharmaceutical according to claim 5, which further comprises a lubricant.

7. (original): The pharmaceutical according to claim 6, wherein the lubricant is magnesium stearate, calcium stearate or talc.

8. (currently amended): The pharmaceutical according to claim ~~6~~ 7, wherein the lubricant is magnesium stearate.

9. (original): The pharmaceutical according to claim 8, which further comprises 0.1 to 2 parts of sodium lauryl sulfate based on 1 part of magnesium stearate.

10. (currently amended): The pharmaceutical according to ~~any one of claims 1 to 9~~ 6, wherein a dosage form is in the form of a capsule or a tablet.

11. (currently amended): The pharmaceutical according to claim 10, wherein the capsule is a light-shielding capsule, ~~or the tablet is coated with a light-shielding coating agent.~~

12. (original): The pharmaceutical according to claim 11, wherein the light- shielding capsule is a capsule containing titanium oxide.

PRELIMINARY AMENDMENT  
National Stage Application of  
PCT/JP2003/015837

Claim 13. (canceled).

14. (currently amended): The pharmaceutical according to ~~any one of claims 1 to 13~~ claim 1, which further comprises, as an active ingredient, at least one member selected from the group consisting of an  $\alpha_1$ -adrenoceptor blocking agent, an anticholinergic agent, an antiinflammatory agent and an antibacterial agent other than ~~an~~ the indoline compound of claim 1.

15. (currently amended): A pharmaceutical for the treatment of dysuria, which comprises a pharmaceutical according to ~~any one of claims 1 to 14~~ claim 1, in combination with a pharmaceutical comprising, as an active ingredient, at least one member selected from the group consisting of an  $\alpha_1$ -adrenoceptor blocking agent, an anticholinergic agent, an antiinflammatory agent and an antibacterial agent other than ~~an~~ the indoline compound of claim 1.

16. (currently amended): The pharmaceutical according to ~~any one of claims 1 to 15~~ claim 1, which is used for the treatment of dysuria.

17. (original): The pharmaceutical according to claim 16, wherein the dysuria is associated with urethra organized blockage, disorders of urination control nerve or urethra functional blockage.

18. (original): The pharmaceutical according to claim 16, wherein the dysuria is associated with prostate hypertrophy, neurogenic bladder or a lower urinary tract disorder.

PRELIMINARY AMENDMENT  
National Stage Application of  
PCT/JP2003/015837

19. (new): The pharmaceutical according to claim 6, wherein a dosage form is in the form of a tablet.

20. (new): The pharmaceutical according to claim 19, wherein the tablet is coated with a light-shielding coating agent.

21. (new): The pharmaceutical according to claim 20, wherein the light-shielding coating agent is a coating agent containing titanium oxide.

22. (new): The pharmaceutical according to claim 4, which comprises D-mannitol as a filler.

23. (new): The pharmaceutical according to claim 22, which further comprises a lubricant.

24. (new): The pharmaceutical according to claim 23, wherein the lubricant is magnesium stearate, calcium stearate or talc.

25. (new): The pharmaceutical according to claim 23, wherein the lubricant is magnesium stearate.

26. (new): The pharmaceutical according to claim 25, which further comprises 0.1 to 2 parts of sodium lauryl sulfate based on 1 part of magnesium stearate.